Detalles de la búsqueda
1.
PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution.
Front Oncol
; 9: 707, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31448227
2.
Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution.
Front Oncol
; 9: 967, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31598491
Resultados
1 -
2
de 2
1
Próxima >
>>